Pembrolizumab is in development for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiotherapy. cSCC is a type of skin cancer that develops in the outermost layer of the skin. Certain factors can increase an individual’s risk of developing cSCC, such as exposure to the sun, […]
Leukocyte interleukin (LI) in combination with cyclophosphamide, indomethacin, and zinc is in clinical development for previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity and soft palate. SCCHN is a cancer that begins in the squamous cells (thin, flat cells that line various organs and skin) in […]
Lenvatinib in combination with pembrolizumab is being developed as a first-line therapy for adultswith programmed death-ligand 1 (PD-L1) expressing recurrent or metastatic head and necksquamous cell carcinoma (HNSCC). HNSCC is a cancer of the mouth, nose or throat that developsin the squamous cells found in the outer layer of skin and the mucous membranes that […]
Tislelizumab is in clinical development to treat patients with localised oesophageal squamous cell carcinoma (ESCC). ESCC begins in the food pipe (oesophagus) and may spread to other parts of the body. Localised cancer is when it is still located only in the tissue or organ where it started, and has not spread to nearby lymph […]
Cemiplimab is an intravenous drug under development for advanced cSCC. It acts on specific proteins on immune cells, allowing the defence system of the body to inhibit the growth of the cancer cells. For patients who develop advanced cSCC, there are limited treatment options available. If licensed, cemiplimab may offer a new licenced treatment option […]
